GlassScriptPhysician profile
Andrew B Demo
NPI 1487040804
$2,566.83
in general payments reported to CMS, 2019-2025
25 companies · $363 in 2025
The $363 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $233 · 2021: $163 · 2022: $356 · 2023: $429 · 2024: $521 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $480.73 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $430.05 | 2021-2024 | Azstarys |
| Cranial Technologies, INC | $352.58 | 2019-2025 | Doc Band |
| Pfizer INC. | $299.84 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.06 | 2019-2022 | |
| Sanofi Pasteur INC. | $109.75 | 2019-2025 | |
| Sobi, INC | $82.65 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $77.89 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Glaxosmithkline, LLC. | $74.64 | 2023-2025 | Bexsero, Rotarix, Pediarix |
| Tris Pharma INC | $64.38 | 2022-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $63.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $54.87 | 2019 | |
| Biomarin Pharmaceutical INC. | $54.01 | 2025 | Voxzogo 1.2mg |
| Adlon Therapeutics L.P. | $41.21 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $34.01 | 2025 | Alvesco |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $29.59 | 2021-2022 | |
| Neos Therapeutics, LP | $29.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $15.90 | 2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $15.85 | 2025 | Jornay Pm |
| Kaleo, INC. | $15.64 | 2022 | |
| Exeltis, USA INC. | $14.94 | 2024 | Slynd |
| Horizon Therapeutics Plc | $14.41 | 2019 | |
| Shire North American Group INC | $13.98 | 2019 | |
| Alk-Abello, INC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Demo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.